Phase 1b study of AMG 757, a halflife extended bispecific T-cell engager (HLE BiTEimmuneoncology therapy) targeting DLL3, in De novo or treatment emergent neuroendocrine prostate cancer (NEPC)

Category Primary study
JournalJournal of Clinical Oncology
Year 2021
This article has no abstract
Epistemonikos ID: ad5649906cb2ef1e62641f270923b3b0396e2204
First added on: Feb 13, 2025